STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase II Clinical Trial

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Trial Number: 05727176
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations